hlx22
HER2-low Hormone Receptor Positive Breast Cancer
Shanghai Henlius BiotechPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
116 Active assets in the HER2-low Hormone Receptor Positive Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Ellipses Pharma | Phase 4 | BBB |
EXEMESTANE Fujian Cancer Hospital | Phase 4 | BBB |
Arimidex University of Illinois at Chicago | Phase 4 | BBB |
Ribociclib BeOne Medicines | Phase 4 | BBB |
Palbociclib BeOne Medicines | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
hlx22 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →